

LITERATURA

- World Health Organization. Dementia fact sheet. 2023. Available from: <https://www.who.int/news-room/fact-sheets/detail/dementia>
- Vaňková H, Hrnčiariková D, Závadová I, et al. Mezioborová klinická doporučení pro diagnostiku a léčbu Alzheimerovy nemoci: „Bílá kniha paliativní péče“ v aktuálním kontextu. Geri a gero. 2024;(1):47-51.
- Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Demence Novelizace 2024. Available from: <http://svl.cz/doporucene-postupy/demence-100017>
- Kleinová L, Cerman J, Hlávka J, et al. Nové farmakologické možnosti v léčbě Alzheimerovy nemoci. Česk Slov Neurol N. 2022;85(6):462-469.
- Hoy SM. Lecanemab: First approval. Drugs. 2023;83(4):359–365. doi: 10.1007/s40265-023-01851-2.
- Nelson S, Lopez O. Lecanemab for Alzheimer disease. Neurology. 2024; 102 (7). e209265. doi: 10.1212/WNL.0000000000209265.
- Lapka M. Lecanemab. Remedia. 2023;33:73-76.
- Eisai global. New release. March 22, 2024. Available from: <https://www.eisai.com/news/2024/news202417.html>
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. doi: 10.1056/NEJMoa2212948.
- Gueorguieva I, Willis BA, Chua L, et al. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease. Clin Pharmacol Ther. 2023; 113(6):1258-1267. doi: 10.1002/cpt.2875.
- Lo A C, Duggan EC, Wessels AM, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384(18):1691-1704.
- The New York Times. March 8, 2024. Available from: <https://www.nytimes.com/2024/03/08/health/alzheimers-drug-donanemab.html>
- Qiao Y, Gu J, Yu M, et al. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. CNS Drugs. 2024 Mar;38(3):169-192. doi: 10.1007/s40263-024-01067-2.
- Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US. JAMA Neurol. 2022;79(5):478-487. doi: 10.1001/jamaneurol.2022.0315.
- Nguyen HV, Mital S, Knopman DS, Alexander GC. Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease. Neurology. 2024;102:e209218. doi: 10.1212/WNL.0000000000209218.
- Lu X, Liu C, Shao F. Phototherapy improves cognitive function in dementia: A systematic review and meta-analysis. Brain Behav. 2023 May;13(5):e2952. doi: 10.1002/brb3.2952.
- Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev. 2016 Jan 13;2016(1):CD011145. doi: 10.1002/14651858.CD011145.
- Tao T, Feng G, Fang Y. Association between aspirin use and risk of dementia: a systematic review and meta-analysis. Eur Geriatr Med. 2024;15(1):3-18. doi: 10.1007/s41999-023-00877-9.
- Xu M, Zhu Y, Chen J et al. Effects of folic acid supplementation on cognitive impairment: A meta-analysis of randomized controlled trials. J Evid Based Med. 2024;17(1):134-144. doi: 10.1111/jebm.12588.
- Akhgarjand C, Vahabi Z, Shab-Bidar S, et al. The effects of probiotic supplements on oxidative stress and inflammation in subjects with mild and moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Inflammopharmacology. 2024;32(2):1413-1420. doi: 10.1007/s10787-023-01427-2.

Pro věrné čtenáře

Součástí Vnitřního lékařství 4/2024 je navíc supplemendum
Zaznělo na 2. diabetologii pro praxi v Olomouci.

Pokud se chcete o 2. diabetologii pro praxi dozvědět více,
na www.diabetologiepropraxi.cz/archiv najdete tiskovou
zprávu a také malou fotogalerii z této vzdělávací akce. →

